The short version of circadian rhythm fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-28. Anything still debated is marked as such rather than presented as settled.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water; stock solutions use organic solvent. |
| Storage | -20°C, desiccated, protected from light | Limits hydrolysis and photodegradation. |
| Analytical method | HPLC-UV/MS | Used for identity and purity assessment. |
| Synonyms | SR9009, Stenabolic | Naming varies by supplier. |
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
==== Methadone clinics ==== In the United States, prescription of methadone requires intensive monitoring and must be obtained in-person from an Opioid Treatment Program—colloquially known as a 'methadone clinic'—when prescribed for opioid use disorder (OUD). According to federal laws, methadone cannot be prescribed by a doctor and obtained from a pharmacy to treat addiction. Because of its long half-life, methadone is almost invariably prescribed to be taken in a single daily dose. At nearly all methadone clinics in the US, patients must visit a clinic to receive and take their dose under the supervision of a nurse. Patients earn take home bottles with their daily dose, by providing clean drug tests and doing therapy. These bottles will be taken away if they provide a dirty drug test, or break clinic rules. They can be earned back. Both patients who are new to methadone treatment and high-risk patients—such as those who are using drugs and alcohol, including cannabis in some states—must visit the clinic daily.
In 2022, mRNA-4157/V940 drug candidate, a cancer vaccine, was studied alongside pembrolizumab for treatment of skin and pancreatic cancers. mRNA-4157/V940 went on to be granted breakthrough therapy designation by the FDA.
=== Solar cells === Single-crystal silicon solar cells are now widely available at low cost. The technology behind these solar devices—which provide up to 50% more power than conventional solar cells—originated with the efforts of a NASA-sponsored 28-member coalition forming the Environmental Research Aircraft and Sensor Technology (ERAST) Alliance. ERAST's goal was to develop remotely piloted aircraft, intended to fly unmanned at high altitudes for days at a time and requiring advanced solar power sources that did not add weight. As a result, SunPower Corporation created advanced silicon-based cells for terrestrial or airborne applications.
Sources: en.wikipedia.org
== Medical uses == Flibanserin is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to: a co-existing medical or psychiatric condition; problems within the relationship, or the effects of a medication or other drug substance. The effectiveness of flibanserin was evaluated in three phase III clinical trials. Each of the three trials had two co-primary endpoints, one for satisfying sexual events (SSEs) and the other for sexual desire. Each of the three trials also had a secondary endpoint that measured distress related to sexual desire. All three trials showed that flibanserin produced an increase in the number of satisfying sexual events and reduced distress related to sexual desire. The first two trials used an electronic diary to measure sexual desire and did not find an increase. These two trials also measured sexual desire using the Female Sexual Function Index (FSFI) as a secondary endpoint, and an increase was observed using this latter measure. The FSFI was used as the co-primary endpoint for sexual desire in the third trial, and again showed a statistically significant increase. Supportive analyses based on the patient's perspective of her symptoms at the end of the study showed that improvements in symptoms of hypoactive sexual desire disorder were not only statistically significant but also clinically meaningful to women.
=== Books === With Huck Gutman, Outsider in the White House. London: Verso Books. 2015 [1997]. ISBN 978-1-78478-418-8. OCLC 918986570. In Robert McChesney; Russell Newman; Ben Scott, eds. (2005). "Why Americans Should Take Back the Media". The Future of Media: Resistance and Reform in the 21st Century. Seven Stories Press. ISBN 978-1-58322-679-7. OCLC 57574152. The Speech: A Historic Filibuster on Corporate Greed and the Decline of Our Middle Class. New York: Bold Type Books. 2015 [2011]. ISBN 978-1-56858-554-3. LCCN 2011920256. OCLC 927456901. OL 25090387M. Our Revolution: A Future to Believe In. Thomas Dunne Books. 2016. ISBN 978-1-250-13292-5. OCLC 1026148801. Bernie Sanders Guide to Political Revolution. Henry Holt and Company. 2017. ISBN 978-1-250-13890-3. OCLC 999379791. Where We Go from Here: Two Years in the Resistance. Gale. 2018. ISBN 978-1-432-86916-8. OCLC 1126540640. It's OK to Be Angry About Capitalism. Crown Books. 2023. ISBN 978-0593238714. Fight Oligarchy, Crown Books, Oct. 2025. ISBN 979-8-217-08916-1
==== Putative receptor targets ==== The table highlights several common cannabinoids along with putative receptor targets and therapeutic properties. Exogenous (plant-derived) phytocannabinoids are identified with an asterisk while remaining chemicals represent well-known endocannabinoids (i.e., endogenously produced cannabinoid receptor ligands).
Guinness Bitter, an English-style bitter beer: 4.4% ABV. Guinness Extra Smooth, a smoother stout sold in Ghana, Cameroon and Nigeria: 5.5% ABV. Malta Guinness, a non-alcoholic beverage, produced in Nigeria and exported to the UK, East Africa, and Malaysia. Guinness Zero ABV, a non-alcoholic beverage sold in Indonesia. Guinness Mid-Strength, a low-alcohol stout test-marketed in Limerick, Ireland in March 2006 and Dublin from May 2007: 2.8% ABV. Guinness Red, brewed in exactly the same way as Guinness except that the barley is only lightly roasted so that it produces a lighter, slightly fruitier red ale; test-marketed in Britain in February 2007: 4% ABV. 250 Anniversary Stout, released in the U.S., Australia and Singapore on 24 April 2009; 5% ABV. Guinness West Indies, a Porter which imitates the 1801 variety with notes of toffee and chocolate: 6% ABV. In October 2005, Guinness announced the Brewhouse Series, a limited-edition collection of draught stouts available for roughly six months each. There were three beers in the series.
Sources: en.wikipedia.org
=== List of well known fractionation effects === A number of common processes fractionate hydrogen isotopes to produce the isotope variations found in nature. Common physical processes include precipitation and evaporation. Chemical reactions can also heavily influence the partitioning of heavy and light isotopes between pools. The rate of a chemical reaction depends in part on the energies of the chemical bonds formed and broken in the reaction. Since different isotopes have different masses, the bond energies differ between isotopologues of a chemical species. This will result in a difference in the rate of a reaction for the different isotopologues, resulting in a fractionation of the different isotopes between the reactant and product in a chemical reaction. This is known as the kinetic isotope effect (KIE). A classic example of KIE is the DHR difference in the equilibrium between H2O and H2 which can have an α value of as much as 3–4.
In the United States, it is against federal regulations for supplement manufacturers to claim that their products prevent or treat any disease. Companies are allowed to use what is referred to as "Structure/Function" wording if there is substantiation of scientific evidence for a supplement providing a potential health effect. An example would be "_____ helps maintain healthy joints", but the label must bear a disclaimer that the Food and Drug Administration (FDA) "has not evaluated the claim" and that the dietary supplement product is not intended to "diagnose, treat, cure or prevent any disease", because only a medication can legally make such a claim. The FDA enforces these regulations as well as prohibiting the sale of supplements and supplement ingredients that are dangerous, or supplements not made according to standardized good manufacturing practices (GMPs). The European Commission has established harmonized rules to help insure that food supplements in the European Union are safe and appropriately labeled.
For South Africa and the Soviet Union—the two parties which had previously refrained from joining the US-mediated talks—the point had now been reached where the costs of continuing the war exceeded its anticipated benefits. This necessitated a change in perceptions in both nations, which began warming to the possibility of a negotiated peace. The Soviet government agreed to jointly sponsor with the US a series of renewed peace talks on 3 and 4 May 1988. For its part, South Africa made its first bid to join the tripartite negotiations and agreed to send a delegation of diplomats, intelligence chiefs, and senior SADF officers. The Soviet and US diplomats in attendance, including Crocker, made it clear to the South Africans that they wanted peace in Angola and a political settlement in South West Africa. They were also agreed on the need to bring pressure on their respective allies to bring about a solution. South Africa would be expected to comply with United Nations Security Council Resolution 435, in exchange for the complete withdrawal of Cuban troops from Angola. The Cuban and Angolan delegations had already assented to a complete Cuban withdrawal, and under US pressure produced an extremely precise timetable which extended this process over three to four years. South Africa found this unacceptable but conceded that the withdrawal could be timed to certain benchmarks in the Namibian independence process. According to Crocker, the US decision to use Security Council Resolution 435 as the basis and pivot for a regional settlement provided leverage over the discussions.
Sources: en.wikipedia.org
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.
The solid is generally kept cold, dry, and protected from light. Solutions are often frozen in single-use aliquots to reduce repeated freeze-thaw cycles.
It indicates a material sold for laboratory study, not for human use. The label does not guarantee pharmaceutical purity, sterility, or regulatory approval.
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.